Loading stock data…
IMMX
$9.56+0.08 (+0.84%)
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immix Biopharma, Inc. in the Healthcare sector is trading at $9.56. The stock is currently 18% below its 52-week high of $11.61, remaining 81.1% above its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why IMMX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.56
Potential Upside
5%
Whystock Fair Value$10.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead prod...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$539.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.39%
Volume
Today's trading volume
899,914
Recent News
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?
Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Immix Biopharma completed enrollment for its NEXICART-2 Phase 2 clinical trial, a key step toward seeking regulatory approval for NXC-201. This therapy targets relapsed/refractory AL Amyloidosis, a condition where the immune system produces toxic proteins […]
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Immix Biopharma...
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX)
We feel now is a pretty good time to analyse Immix Biopharma, Inc.'s ( NASDAQ:IMMX ) business as it appears the company...
We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Immix...
Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insiders
Key Insights Immix Biopharma's significant individual investors ownership suggests that the key decisions are...